Research programme: cancer therapeutics - SHAL Technologies

Drug Profile

Research programme: cancer therapeutics - SHAL Technologies

Alternative Names: SH 7113; SH 7129; SH 7133; SH 7139; SHALs

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SHAL Technologies
  • Developer Lawrence Livermore National Laboratory; SHAL Technologies; University of california davis medical center
  • Class Small molecules
  • Mechanism of Action HLA-DR10 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 04 Apr 2017 Adverse events data from a preclinical trials presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 24 Jul 2015 SHAL Technologies and University of Carolina plan a phase Ia/II trial for Non-hodgkin's lymphoma in USA (SHAL Technologies website, July 2015)
  • 23 Jul 2015 Preclinical trials in Leukaemia in USA (unspecified route) before July 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top